摘要
尾加压素II（Urotensin II）与尾加压素II受体（ Urotensin-II receptors）是调节血管收缩和与血压调节异常有关的所有疾病（如：高血压、肾脏病、肝硬化等）的重要分子因素。尾加压素Ⅱ及其受体参与了代谢综合征、糖尿病和精神分裂症。近期研究结果表明，尾加压素Ⅱ及其受体与不同上皮性肿瘤的发生和发展有关。事实上，据报道，细胞生长、人乳腺癌、膀胱癌、前列腺癌、结直肠肿瘤和胶质母细胞瘤细胞的运动和侵袭是由尾加压素II（Urotensin II）和尾加压素II受体（ Urotensin-II receptors）轴调节的。这条轴线也调节粘着斑激酶和5''鸟苷三磷酸结合蛋白，该蛋白可能参与了尾加压素II受体介导的细胞运动和攻击。此外，在肿瘤组织中的表达变化对患者临床结果的预测有关，它可以被认为是作为人类癌症的预后因子的另一种分子标记。总之，在人类癌症治疗中的一个新的武器是突现未来的一个新的方案。
关键词: 尾加压素II受体，消化道癌症，癌症的预测标志物
图形摘要
[1]
Douglas, S.A.; Ohlstein, E.H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardivascular diseases. Trends Cardiovasc. Med., 2000, 10, 229-237.
[2]
Grieco, P.; Rovero, P.; Novellino, E. Recent Structure Activity Studies of the Peptide Hormone Urotensin-II: A Potent Vaso-constrictor. Curr. Med. Chem., 2003, 10, 1241-1253.
[3]
Pearson, D.; Shively, J.E.; Clark, B.R.; Geschwind, I.I.; Barkley, M.; Nishioka, R.S.; Bern, H.A. Urotensin II: a somatostain-like peptide in the caudal neurosecretory system of fishes. Proc. Natl. Acad. Sci. USA, 1980, 77, 5021-5024.
[4]
Davenport, A.P.; Maguire, J.J.; Urotensin, I.I. Fish neuropeptide catches orphan receptor. Trends Pharmacol. Sci., 2000, 21, 80-82.
[5]
Marchese, A.; Heiber, M.; Nguyen, T.; Heng, H.H.; Saldivia, V.R.; Cheng, R.; Murphy, P.M.; Tsui, L.C.; Shi, X.; Gregor, P.; George, S.R.; O’Dowd, B.F.; Docherty, J.M. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics, 1995, 29, 335-344.
[6]
Douglas, S.A.; Ashton, D.J.; Sauermelch, C.F.; Coatney, R.W.; Ohlstein, D.H.; Ruffolo, M.R.; Ohlstein, E.H.; Aiyar, N.V.; Willette, R.N. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J. Cardiovasc. Pharmacol., 2000, 36(5)(Suppl. 1), S163-S166.
[7]
Mc Master, D.; Kobayashi, Y.; Rivier, J.; Lederis, K. Characterization of the biologically and antigenically important regions of urotensin II. Proc. West. Pharmacol. Soc., 1986, 29, 205-208.
[8]
Chatenet, D.; Dubessy, C.; Leprince, J.; Boularan, C.; Carlier, L.; Ségalas-Milazzo, I.; Guilhaudis, L.; Oulyadi, H.; Davoust, D.; Scalbert, E.; Pfeiffer, B.; Renard, P.; Tonon, M.C.; Lihrmann, I.; Pacaud, P.; Vaudry, H. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptide, 2004, 25, 1819-1830.
[9]
Nothacker, H.P.; Wang, Z.; McNeill, A.M.; Saito, Y.; Merten, S.; O’Dowd, B.; Duckles, S.P.; Civelli, O. Identification of the natural liogand of an orphan G- protein coupled receptor involved in the regulation of vasoconstriction. Nat. Cell Biol., 1999, 1, 383-385.
[10]
Mori, M.; Sugo, T.; Abe, M.; Shimomura, Y.; Kurihara, M.; Kitada, C.; Kikuchi, K.; Shintani, Y.; Kurokawa, T.; Onda, H.; Nishimura, O.; Fujino, M. Urotensin II is the endogenous ligand of a G-protein coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun., 1999, 265, 123-129.
[11]
Liu, Q.; Pong, S.S.; Zeng, Z.; Zhang, Q.; Howard, A.D.; Williams, D.L., Jr; Davidoff, M.; Wang, R.; Austin, C.P.; McDonald, T.P.; Bai, C.; George, S.R.; Evans, J.F.; Caskey, C.T. Identification of urotensin II as the endogenous ligand for the orphan G-protein coupled receptor GPR14. Biochem. Biophys. Res. Commun., 1999, 266, 174-178.
[12]
Libert, F.; Vassart, G.; Parmentier, M. Current developments in G-protein- coupled receptors. Curr. Opin. Cell Biol., 1991, 8, 218-223.
[13]
Ames, R.S.; Sarau, H.M.; Chambers, J.K.; Willette, R.N.; Aiyar, N.V.; Romanic, A.M.; Louden, C.S.; Foley, J.J.; Sauermelch, C.F.; Coatney, R.W.; Ao, Z.; Disa, J.; Holmes, S.D.; Stadel, J.M.; Martin, J.D.; Liu, W.S.; Glover, G.I.; Wilson, S.; McNulty, D.E.; Ellis, C.E.; Elshourbagy, N.A.; Shabon, U.; Trill, J.J.; Hay, D.W.; Ohlstein, E.H.; Bergsma, D.J.; Douglas, S.A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 1999, 401, 282-286.
[14]
Matsushita, M.; Shichiri, M.; Imai, T.; Iwashina, M.; Tanaka, H.; Takasu, N.; Hirata, Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens., 2001, 19, 2185-2190.
[15]
Douglas, S.A.; Tayara, L.; Ohlstein, E.H.; Halawa, N.; Giaid, A. Congestive heart failure and expression of myocardial urotensin II. Lancet, 2002, 359, 1990-1997.
[16]
Dubessy, C.; Cartier, D.; Lectez, B.; Bucharles, C.; Chartrel, N.; Montero-Hadjadje, M.; Bizet, P.; Chatenet, D.; Tostivint, H.; Scalbert, E.; Leprince, J.; Vaudry, H.; Jégou, S.; Lihrmann, I. Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction. J. Neurochem., 2008, 107, 361-374.
[17]
Chartrel, N.; Leprince, J.; Dujardin, C.; Chatenet, D.; Tollemer, H.; Baroncini, M.; Balment, R.J.; Beauvillain, J.C.; Vaudry, H. Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. J. Neurochem., 2004, 91, 110-118.
[18]
MacLean, M.R.; Alexander, D.; Stirrat, A.; Gallagher, M.; Douglas, S.A.; Ohlstein, E.H.; Morecroft, I.; Polland, K. Contractile response to human urotensin- II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol., 2000, 130, 201-204.
[19]
Douglas, S.A.; Sulpizio, A.C.; Piercy, V.; Sarau, H.M.; Ames, R.S.; Aiyar, N.V.; Ohlstein, E.H.; Willette, R.N. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br. J. Pharmacol., 2001, 131, 1262-1274.
[20]
Hay, D.; Luttmann, M.A.; Douglas, S.A. Human urotensin-II is a potent spasmogen of primate airway smooth muscle. Br. J. Pharmacol., 2000, 131, 10-12.
[21]
Thanassoulis, G.; Huyhn, T.; Giaid, A. Urotensin II and cardiovascular diseases. Peptides, 2004, 25, 1789-1794.
[22]
Zhu, Y.C.; Zhu, Y.Z.; Moore, P.K. The role of Urotensin II in cardiovascular and renal physiology and diseases. Br. J. Pharmacol., 2006, 148, 884-901.
[23]
Conlon, J.M.; Yano, K.; Waugh, D.; Hazon, N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J. Exp. Zool., 1996, 275, 226-238.
[24]
Coulouarn, Y.; Lihrmann, I.; Jegou, S.; Anouar, Y.; Tostivint, H.; Beauvillain, J.C.; Conlon, J.M.; Bern, H.A.; Vaudry, H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. USA, 1998, 95, 15803-15808.
[25]
Vaudry, H.; Leprince, J.; Chatenet, D.; Fournier, A.; Lambert, D.G.; Le Mével, J.C.; Ohlstein, E.H.; Schwertani, A.; Tostivint, H.; Vaudry, D. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol. Rev., 2015, 67, 214-258.
[26]
Saetrum Opgaard, O.; Nothacker, H.; Ehlert, F.J.; Krause, D.N. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur. J. Pharmacol., 2000, 406, 265-271.
[27]
Parys, J.B.; De Smedt, H. Inositol 1,4,5-trisphosphate and its receptors. Adv. Exp. Med. Biol., 2012, 740, 255-279.
[28]
Ziltener, P.; Mueller, C.; Haenig, B.; Scherz, M.W.; Nayler, O. Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. J. Recept. Signal Transduct. Res., 2002, 22, 155-168.
[29]
Sauzeau, V.; Le Mellionnec, E.; Bertoglio, J.; Scalbert, E.; Pacaud, P.; Loirand, G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ. Res., 2001, 88, 1102-1104.
[30]
Joyal, D.; Huynh, T.; Aiyar, N.; Guida, B.; Douglas, S.; Giaid, A. Urotensin-II levels in acute coronary syndromes. Int. J. Cardiol., 2006, 108(1), 31-35.
[31]
Gruson, D.; Ginion, A.; Decroly, N.; Lause, P.; Vanoverschelde, J.L.; Ketelslegers, J.M.; Bertrand, L.; Thissen, J.P. Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides, 2010, 31, 1326-1333.
[32]
Behm, D.J.; Ao, Z.; Camarda, V.; Aiyar, N.V.; Johns, D.G.; Douglas, S.A. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle. Eur. J. Pharmacol., 2005, 516, 276-281.
[33]
Trebicka, J.; Leifeld, L.; Hennenberg, M.; Biecker, E.; Eckhardt, A.; Fischer, N.; Pröbsting, A.S.; Clemens, C.; Lammert, F.; Sauerbruch, T.; Heller, J. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology, 2008, 47(4), 1264-1276.
[34]
Pehlivan, Y.; Dokuyucu, R.; Demir, T.; Kaplan, D.S.; Koc, I.; Orkmez, M.; Turkbeyler, I.H.; Ceribasi, A.O.; Tutar, E.; Taysi, S.; Kisacik, B.; Onat, A.M. Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension. Inflammation, 2014, 37, 1280-1288.
[35]
He, W.Y.; Chen, G.J.; Lai, X.; Wu, F.; Tang, C.S.; Zhang, A.H. Expression levels of urotensin II are associated with endoplasmic reticulum stress in patients with severe preeclampsia. J. Hum. Hypertens., 2015, 30, 129-135.
[36]
Liu, W.; Han, Q.; Liu, Q.; Liang, G.; Wang, J.; Liu, C. An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts. Mol. Med. Rep., 2015, 12, 6626-6634.
[37]
Oh, K.S.; Lee, J.H.; Yi, K.Y.; Lim, C.J.; Lee, S.; Park, C.H.; Seo, H.W.; Lee, B.H. The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy. Br. J. Pharmacol., 2015, 172, 2618-2633.
[38]
Aita, Y.; Kasahara, T.; Isobe, K.; Kawakami, Y.; Takekoshi, K. Effect of urotensin II on PC12 rat pheochromocytoma cells. J. Neuroendocrinol., 2010, 22(2), 83-91.
[39]
Esposito, G.; Perrino, C.; Cannavo, A.; Schiattarella, G.G.; Borgia, F.; Sannino, A.; Pironti, G.; Gargiulo, G.; Di Serafino, L.; Franzone, A.; Scudiero, L.; Grieco, P.; Indolfi, C.; Chiariello, M. EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Res. Cardiol., 2011, 106, 577-589.
[40]
d’Emmanuele di Villa Bianca, R.; Cirino, G.; Mitidieri, E.; Coletta, C.; Grassia, G.; Roviezzo, F.; Grieco, P.; Novellino, E.; Imbimbo, C.; Mirone, V.; Sorrentino, R. Urotensin II: a novel target in human corpus cavernosum. J. Sex. Med., 2010, 7, 1778-1786.
[41]
di Villa Bianca, Rd.; Mitidieri, E.; Donnarumma, E.; Fusco, F.; Longo, N.; Rosa, G.D.; Novellino, E.; Grieco, P.; Mirone, V.; Cirino, G.; Sorrentino, R. A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands. Asian J. Androl., 2015, 17, 81-85.
[42]
Abdel-Razik, A.E.; Balment, R.J.; Ashton, N. Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II. Am. J. Physiol. Renal Physiol., 2008, 295, 1239-1247.
[43]
Adebiyi, A. RGS2 regulates urotensin II-induced intracellular Ca2+ elevation and contraction in glomerular mesangial cells. J. Cell. Physiol., 2014, 229(4), 502-511.
[44]
Debiec, R.; Christofidou, P.; Denniff, M.; Bloomer, L.D.; Bogdanski, P.; Wojnar, L.; Musialik, K.; Charchar, F.J.; Thompson, J.R.; Waterworth, D.; Song, K.; Vollenweider, P.; Waeber, G.; Zukowska-Szczechowska, E.; Samani, N.J.; Lambert, D.; Tomaszewski, M. Urotensin-II system in genetic control of blood pressure and renal function. PLoS One, 2013, 8(12), e83137.
[45]
Balat, A.; Büyükçelik, M. Urotensin-II: More Than a Mediator for
Kidney. Int. J. Nephrol, 2012. 2012, 249790.
[46]
Heller, J.; Schepke, M.; Neef, M.; Woitas, R.; Rabe, C.; Sauerbruch, T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J. Hepatol., 2002, 37, 767-772.
[47]
Kemp, W.; Krum, H.; Colman, J.; Bailey, M.; Yandle, T.; Richards, M.; Roberts, S. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int., 2007, 27, 1232-1239.
[48]
Rosso, N.; Chavez-Tapia, N.C.; Tiribelli, C.; Bellentani, S. Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World J. Gastroenterol., 2014, 20, 9038-9049.
[49]
Watanabe, T.; Kanome, T.; Suguro, T.; Miyazaki, A. Human Urotensin II and Metabolic Syndrome. Vasc. Dis. Prev., 2006, 3(2), 91-98.
[50]
Xie, N.; Liu, L. Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance. Biomed. Pharmacother., 2009, 63(10), 734-741.
[51]
Elshourbagy, N.A.; Douglas, S.A.; Shabon, U.; Harrison, S.; Duddy, G.; Sechler, J.L.; Ao, Z.; Maleeff, B.E.; Naselsky, D.; Disa, J.; Aiyar, N.V. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein- coupled receptors from the mouse and monkey. Br. J. Pharmacol., 2002, 136, 9-22.
[52]
Totsune, K.; Takahashi, K.; Arihara, Z.; Sone, M.; Ito, S.; Murakami, O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci., 2003, 104, 1-5.
[53]
Leifeld, L.; Clemens, C.; Heller, J.; Trebicka, J.; Sauerbruch, T.; Spengler, U. Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. Dig. Dis. Sci., 2010, 55(5), 1458-1464.
[54]
You, Z.; Al Kindi, H.; Abdul-Karim, A.; Barrette, P.O.; Schwertani, A. Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice. FASEB J., 2014, 28, 1210-1220.
[55]
Barrette, P.O.; Schwertani, AG. A closer look at the role of urotensin II in the metabolic syndrome. Front Endocrinol. (Lausanne), 2012. 28, 3, 165.
[56]
You, Z.; Genest, J., Jr; Barrette, P.O.; Hafiane, A.; Behm, D.J.; D’Orleans-Juste, P.; Schwertani, A.G. Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice. Arterioscler. Thromb. Vasc. Biol., 2012, 32, 1809-1816.
[57]
Bulbul, F.; Alpak, G.; Unal, A.; Copoglu, U.S.; Orkmez, M.; Virit, O.; Tarkcıoglu, M.; Savas, H.A. New molecule in the etiology of schizophrenia: urotensin II. Psychiatry Clin. Neurosci., 2014, 68, 133-136.
[58]
Romanelli, R.G.; Laffi, G.; Vizzutti, F.; Del Bene, R.; Marra, F.; Caini, P.; Guerra, C.T. La villa, G.; Barletta, G. Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis. Dig. Liver Dis., 2011, 43(4), 314-318.
[59]
Kristof, A.S.; You, Z.; Han, Y.S.; Giaid, A. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis. Peptides, 2010, 31, 1511-1516.
[60]
Federico, A.; Zappavigna, S.; Romano, M.; Grieco, P.; Luce, A.; Marra, M.; Gravina, A.G.; Stiuso, P.; D’Armiento, F.P.; Vitale, G.; Tuccillo, C.; Novellino, E.; Loguercio, C.; Caraglia, M. Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. Eur. J. Clin. Invest., 2014, 44, 285-294.
[61]
Grieco, P.; Franco, R.; Bozzuto, G.; Toccacieli, L.; Sgambato, A.; Marra, M.; Zappavigna, S.; Migaldi, M.; Rossi, G.; Striano, S.; Marra, L.; Gallo, L.; Cittadini, A.; Botti, G.; Novellino, E.; Molinari, A.; Budillon, A.; Caraglia, M. Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. J. Cell. Biochem., 2011, 112, 341-353.
[62]
Giuliani, L.; Lenzini, L.; Antonello, M.; Aldighieri, E.; Belloni, A.S.; Fassina, A.; Gomez-Sanchez, C.; Rossi, G.P. Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism. J. Clin. Endocrinol. Metab., 2009, 94, 684-690.
[63]
Franco, R.; Zappavigna, S.; Gigantino, V.; Luce, A.; Cantile, M.; Cerrone, M.; Facchini, G.; Perdonà, S.; Pignata, S.; Di Lorenzo, G.; Chieffi, S.; Vitale, G.; De Sio, M.; Sgambato, A.; Botti, G.; Yousif, A.M.; Novellino, E.; Grieco, P.; Caraglia, M. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. J. Exp. Clin. Cancer Res., 2014, 33, 48.
[64]
Wang, H.; Dong, K.; Xue, X.; Feng, P.; Wang, X. Elevated expression of urotensin II and its receptor in diethylnitrosamine-mediated precancerous lesions in rat liver. Peptides, 2011, 32, 382-387.
[65]
Yu, X.T.; Wang, P.Y.; Shi, Z.M.; Dong, K.; Feng, P.; Wang, H.X.; Wang, X.J. Up-regulation of urotensin II and its receptor contributes to human hepatocellular carcinoma growth via activation of the PKC, ERK1/2, and p38 MAPK signaling pathways. Molecules, 2014, 19, 20768-20779.
[66]
Balakan, O.; Kalender, M.E.; Suner, A.; Cengiz, B.; Oztuzcu, S.; Bayraktar, R.; Borazan, E.; Babacan, T.; Camci, C. The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med. Sci. Monit., 2014, 20, 1419-1425.
[67]
Ross, B.; McKendy, K.; Giaid, A. Role of urotensin II in health and disease. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 298(5), R1156-R1172.
[68]
Takahashi, K.; Totsune, K.; Murakami, O.; Shibahara, S. Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides, 2001, 22, 1175-1179.
[69]
Takahashi, K.; Totsune, K.; Murakami, O. Expression of three vasoactive peptides, urotensin II, adrenomedullin and endothelin-1, in a human renal cell carcinoma cell line, VMRC-RCW. Clin. Exp. Nephrol., 2002, 5, 246-249.
[70]
Takahashi, K.; Totsune, K.; Kitamuro, T.; Sone, M.; Murakami, O.; Shibahara, S. Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumor cell lines of different origin: expression and effects on proliferation. Clin. Sci., 2000, 103, 35-38.
[71]
Johansson, J.E.; Holmberg, L.; Johansson, S.; Bergström, R.; Adami, H.O. Fifteen year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA, 1997, 277, 467-471.
[72]
Albertsen, P.C.; Hanley, J.A. Fine 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA, 2005, 293, 2095-2101.
[73]
Halabi, S.; Small, E.J.; Kantoff, P.W.; Kattan, M.W.; Kaplan, E.B.; Dawson, N.A. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol., 2003, 21, 1232-1237.
[74]
Gleason, D.F.; Mellinger, G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 1974, 11, 58-64.
[75]
Cobelli, O.; Buonerba, C.; Terracciano, D.; Danilo, B.; Giuseppe, L.; Bove, P.; Altieri, V.; Coman, I.; Perdonà, S.; Facchini, G.; Berretta, M.; Lorenzo, G.D.; Grieco, P.; Novellino, E.; Franco, R.; Caraglia, M.; Manini, C.; Mirone, V.; Placido, S.; Sonpavde, G.; Ferro, M. Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncol., 2015, 11, 3091-3098.
[76]
Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59, 225-249.
[77]
Sengupta, S.; Blute, M.L. The management of superficial transitional cell carcinoma of the bladder. Urology, 2006, 67, 48-54.
[78]
Murphy, W.M.; Takezawa, K.; Maruniak, N.A. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J. Urol., 2002, 168, 968-972.
[79]
Onan, D.; Hannan, R.D.; Thomas, W.G. Urotensin II: the old kid in town. Trends Endocrinol. Metab., 2004, 15, 175-182.
[80]
Yoshimoto, T.; Matsushita, M.; Hirata, Y. Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides, 2004, 25, 1775-1781.
[81]
Watanabe, T. Kanome1, T.; Miyazaki, A.; Katagiri, T. Human Urotensin II as a Link between Hypertension and Coronary Artery Disease. Hypertens. Res., 2006, 29, 375-387.
[82]
Charles, C.J.; Rademaker, M.T.; Richards, A.M.; Yandle, T.G. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides, 2005, 26, 2211-2214.
[83]
Liu, D.; Chen, J.; Wang, J.; Zhang, Z.; Ma, X.; Jia, J.; Wang, Y. Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. Int. J. Mol. Med., 2010, 25, 845-851.
[84]
Janz, N.K.; Wren, P.A.; Schottenfeld, D.; Guire, K.E. Colorectal cancer screening attitudes and behavior: a population-based study. Prev. Med., 2003, 37(6 Pt1), 627-634.
[85]
Haq, S.; Ali, S.; Mohammad, R.; Sarkar, F.H. The complexities of epidemiology and prevention of gastrointestinal cancers. Int. J. Mol. Sci., 2012, 13, 12556-12572.
[86]
Labianca, R.; Beretta, G.; Bozzetti, F.; Milesi, L.; Mosconi, S.; Quadri, A. Neoplasie dell’apparato digerente. Elsevier Masson: Italy, 2009; pp. 1015-1101.
[87]
Qiu, Y.; Zhou, B.; Su, M.; Baxte, S.; Zheng, X.; Zhao, X.; Yen, Y.; Jia, W. Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int. J. Mol. Sci., 2013, 14(4), 8047-8061.
[88]
Winkfield, K.M.; Harris, J.R. Effective local therapy and long-term survival in breast cancer. Oncology, 2009, 23(8), 669-675.
[90]
Yumrutas, O.; Oztuzcu, S.; Büyükhatipoglu, H.; Bozgeyik, I.; Bozgeyik, E.; Igci, Y.Z.; Bagis, H.; Cevik, M.O.; Kalender, M.E.; Eslik, Z.; Arslan, A. The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer. Tumour Biol., 2015, 36, 4427-4432.
[91]
Addeo, R.; Caraglia, M.; De Santi, M.S.; Montella, L.; Abbruzzese, A.; Parlato, C.; Vincenzi, B.; Carraturo, M.; Faiola, V.; Genovese, M.; Cennamo, G.; Del Prete, S. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J. Neurooncol., 2011, 102(3), 417-424. [Erratum in: J. Neurooncol.,2011, 102]. [3].
[92]
Addeo, R.; De Santi, M.S.; Del Prete, S.; Caraglia, M. Fotemustine and recurrentglioblastoma: possible new opportunities for an old drug. Cancer Chemother. Pharmacol., 2009, 64(5), 863-866.
[93]
Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A.A.; Gijtenbeek, J.; Marosi, C.; Vecht, C.J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J.G.; Mirimanoff, R.O. National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 2009, 10, 459-466.
[94]
Desrues, L.; Lefebvre, T.; Lecointre, C.; Schouft, M.T.; Leprince, J.; Compère, V.; Morin, F.; Proust, F.; Gandolfo, P.; Tonon, M.C.; Castel, H. Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity. PLoS One, 2012, 7, e36319.
[95]
Lecointre, C.; Desrues, L.; Joubert, J.E.; Perzo, N.; Guichet, P.O.; Le Joncour, V.; Brulé, C.; Chabbert, M.; Leduc, R.; Prézeau, L.; Laquerrière, A.; Proust, F.; Gandolfo, P.; Morin, F.; Castel, H. Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma. Oncogene, 2015, 34, 5080-5094.
[96]
Brulé, C.; Perzo, N.; Joubert, J.E.; Sainsily, X.; Leduc, R.; Castel, H.; Prézeau, L. Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors. FASEB J., 2014, 28, 5148-5162.
[97]
Grieco, P.; Carotenuto, A.; Campiglia, P.; Zampelli, E.; Patacchini, R.; Maggi, C.A.; Novellino, E.; Rovero, P. A new potent Urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J. Med. Chem., 2002, 45, 4391-4394.
[98]
Novellino, E.; Grieco, P.; Rovero, P. Cyclic peptides acting as
urotensin II antagonists, and use in the treatment of hypertension
and other cardiovascular conditions and in urotensin II receptor
characterization. WO Patent 2005023845 A2, March 17, 2005.
[99]
Chatenet, D.; Dubessy, C.; Boularan, C.; Scalbert, E.; Pfeiffer, B.; Renard, P.; Lihrmann, I.; Pacaud, P.; Tonon, M.C.; Vaudry, H.; Leprince, J. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. J. Med. Chem., 2006, 49(24), 7234-7238.
[100]
Carotenuto, A.; Auriemma, L.; Merlino, F.; Yousif, A.M.; Marasco, D.; Limatola, A.; Campiglia, P.; Gomez-Monterrey, I.; Santicioli, P.; Meini, S.; Maggi, C.A.; Novellino, E.; Grieco, P. Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor. J. Med. Chem., 2014, 57, 5965-5974.
[101]
Grieco, P.; Carotenuto, A.; Campiglia, P.; Marinelli, L.; Lama, T.; Patacchini, R.; Santicioli, P.; Maggi, C.A.; Rovero, P.; Novellino, E. Urotensin-II receptor ligands. From agonist to antagonist activity. J. Med. Chem., 2005, 48, 7290-7297.
[102]
Patacchini, R.; Santicioli, P.; Giuliani, S.; Grieco, P.; Novellino, E.; Rovero, P.; Maggi, C.A. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br. J. Pharmacol., 2003, 140, 1155-1158.
[103]
Chatenet, D.; Létourneau, M.; Nguyen, Q.T.; Doan, N.D.; Dupuis, J.; Fournier, A. Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation. Br. J. Pharmacol., 2013, 168, 807-821.
[104]
Chatenet, D.; Folch, B.; Feytens, D.; Létourneau, M.; Tourwé, D.; Doucet, N.; Fournier, A. Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists. J. Med. Chem., 2013, 56, 9612-9622.
[105]
Chatenet, D.; Nguyen, T.T.; Létourneau, M.; Fournier, A. Update on the urotensinergic system: new trends in receptor localization, activation, and drug design. Front. Endocrinol. (Lausanne), 2013, 3, 174.
[106]
Clozel, M.; Binkert, C.; Birker-Robaczewska, M.; Boukhadra, C.; Ding, S.S.; Fischli, W.; Hess, P.; Mathys, B.; Morrison, K.; Müller, C.; Müller, C.; Nayler, O.; Qiu, C.; Rey, M.; Scherz, M.W.; Velker, J.; Weller, T.; Xi, J.F.; Ziltener, P. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362);1- [2-(4-benzyl-4-hydroxypiperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): First demonstration of a pathophysiological role of the urotensin system. J. Pharmacol. Exp. Ther., 2004, 311, 204-212.
[107]
Kaiser, E.; Colescott, R.L.; Bossinger, C.D.; Cook, P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem., 1970, 34, 595-598.
[108]
Maryanoff, B.E.; Kinney, W.A. Urotensin-II receptor modulators as potential drugs. J. Med. Chem., 2010, 53, 2695-2708.
[109]
Merlino, F.; Di Maro, S.; Munaim Yousif, A.; Caraglia, M.; Grieco, P. Urotensin-II ligands: An overview from peptide to nonpeptide
structures. J. Amino Acids, 2013. 2013, 979016.
[110]
Lescot, E.; Sopkova-de Oliveira Santos, J.; Dubessy, C.; Oulyadi, H.; Lesnard, A.; Vaudry, H.; Bureau, R.; Rault, S. Definition of new pharmacophores for nonpeptide antagonist of human Urotensin-II. Comparison with the 3D-structure of human Urotensin-II and URP. J. Chem. Inf. Model., 2007, 47, 602-612.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
36
3